TCRX

$1.22+0.06 (+5.17%)

Market ClosedLast close May 1

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.

Overview Intraday ResearchPRO BacktestPRO Ask AIPRO TranscriptsPRO StatementsPRO